分享:
分享到微信朋友圈
X
综述
MR扩散加权成像在前列腺癌诊断中的应用进展
陈慧铀 姜亮 王利伟 殷信道

Hui-you to make the same contribution to this workJanesya Sutedjo,陈慧铀,姜亮,等. MR扩散加权成像在前列腺癌诊断中的应用进展.磁共振成像, 2015, 6(7): 554-560. DOI:10.3969/j.issn.1674-8034.2015.05.016.


[摘要] 磁共振成像(MRI)已应用于前列腺癌(PCa)的诊断十多年。扩散加权成像(DWI)做为一种磁共振成像技术,可以在细胞水平提供定性和定量信息。DWI在提高MRI诊断前列腺癌的精确性方面可能发展成一个强大的技术。在这篇文章中,我们将介绍DWI的原理及应用基础、临床应用、局限性及应用前景。
[Abstract] Magnetic resonance imaging (MRI) has been used in prostate cancer (PCa) diagnosis for over a decade. Diffusion weighted imaging (DWI) is one of the methods of the MRI techniques that could provide qualitative as well as quantitative information at a cellular level. DWI potentially could develop into a powerful technique to improve the accuracy of MRI to evaluate the PCa. In this article, we will present the basics of DWI, clinical application, as well as the limitations and the future directions of DWI of PCa.
[关键词] 前列腺肿瘤;弥散磁共振成像;综述文献专题
[Keywords] Prostatic neoplasms;Diffusion magnetic resonance imaging;Review literature as topic

南京医科大学附属南京医院(南京市第一医院)医学影像科,南京 210006

陈慧铀 南京医科大学第三临床学院,南京 210029

姜亮 南京医科大学附属南京医院(南京市第一医院)医学影像科,南京 210006

王利伟* 南京医科大学第三临床学院,南京 210029

殷信道* 南京医科大学附属南京医院(南京市第一医院)医学影像科,南京 210006

通讯作者:殷信道,E-mail:y.163yy@163.com; 王利伟,E-mail:wangliwei_nanjing@ 163.com


收稿日期:2015-02-09
接受日期:2015-04-10
中图分类号:R445.2; R697+.3 
文献标识码:A
DOI: 10.3969/j.issn.1674-8034.2015.05.016
Janesya Sutedjo,陈慧铀,姜亮,等. MR扩散加权成像在前列腺癌诊断中的应用进展.磁共振成像, 2015, 6(7): 554-560. DOI:10.3969/j.issn.1674-8034.2015.05.016.

1 Introduction

       Based on the GLOBOCAN 2012 estimates, prostate cancer (PCa) is the second most commonly diagnosed cancer and the fifth most common cause of cancer death in men worldwide in 2012[1]. An early detection of the PCa is an important part to have an effective treatment of PCa[2].

       For over a decade, magnetic resonance imaging (MRI) has been used in PCa diagnosis with varying degrees of success[3]. Earlier emphasis of prostate MRI relied primarily on morphologic and signal changes present on the conventional MRI, including T1 and T2-weighted images, which gave relatively poor sensitivity and specificity for detecting PCa[4,5]. There are some new technical advancement that lead to the development of anatomical and functional MRI techniques that potentially lead to increased sensitivity, specificity, and accuracy of detection and characterization of disease processes[4, 6]. Of all functional MR imaging techniques, diffusion weighted imaging (DWI) MRI is the most practical and simple in its use[7]. It has several advantages such as: not requiring exogenous contrast material, simple to process, and it requires less time and less technologist training to perform[8]. However it has the disadvantages of being susceptible to motion and to magnetic field inhomogeneities[7]. This article will talk and focus on DWI, its basics, and progress of the DWI application in diagnosing PCa.

2 The basics diffusion of DWI

       DWI is a method to functionally assess tissue and organs of the body by analyzing their cellular structure, that relies on the concept process of the Brownian molecular motion. DWI uses the differences in the motion of water molecules in extracellular and intracellular fluid and vascular fluids to produce image contrast, with no need for exogenous contrast materials[9]. The degree of water diffusion restriction in biologic tissue is oppositely related to the tissue cellularity and the integrity of the cell membranes; the degree of water diffusion is more restricted in tissues that has a high cellular density because of the presence of many intact cell membranes[3, 10]. When measurements of the diffusion are being performed, the water diffusion direction along the three orthogonal directions of the magnet (phase select, frequency select, and slice select) can be assessed independently by applying diffusion gradients in each of these directions. DWI that is the sum of the directionally acquired DWI is known as trace or index DWI[11,12]. The relative change in DWI signal intensity at different b-values can be used to characterize tissues on the basis of differences in water diffusion. Thus, subjective visual assessment of the relative tissue signal changes on DWI using multiple b-values may be useful for tumor detection, tumor characterization and assessment of treatment response[12] .

       Diffusion weighted images taken with at least two different b-values allow for the calculation of the apparent diffusion coefficient (ADC), which can quantify the water diffusion values in the tissue with reflecting the net displacement of water molecules per time (mm2/s) in a given volume element (voxel)[13] . Water motion sensitivity of DWI is determined by the b-value (mm2/s), which reflects the influence of the diffusion sensitizing gradients and can be altered by changing gradient amplitude, gradient duration and time interval between the paired gradients[12,14]. For a useful interpretation, DWI needs to be performed using at least two b-values: b=0 mm2/s and b=100 to 1000 mm2/s[12]. DWI performed with b=0 mm2/s is equal to a T2-weighted sequence. At lower b-values (200 mm2/s or less), the calculated ADC is influenced by tissue perfusion and water diffusivity. Increasing the b-value over 200 mm2/s reduces the effect of perfusion.

       ADC maps of the entire imaged volume can be generated automatically on most MRI scanners and workstations. Average ADC value is determined by drawing an electronic region of interest (ROI) on an ADC map image generated on the scanner. The changes in ADC are inversely correlated with the changes in tissue cellularity: Decreased ADC values compared to normal tissue indicate restricted diffusion. Conversely, increased ADC values suggest increased diffusivity[12].

3 Clinical application of prostate DWI

3.1 Qualitative analysis of DWI

       DWI images can be assessed qualitatively by visual inspection. Water molecules with a large degree of motion (e.g., in blood vessels) have less signal attenuation (remain hyperintense or bright) at small b-values (e.g., b=50—100 mm2/s) and greater signal attenuation (become hypointense or dark) at large b-values. Water molecules motion that slow and restricted (e.g., in PCa) have less signal attenuation (remain hyperintense or bright) at large b-values (e.g., b=500—1000 mm2/s). Overall, the higher the b-value, the more sensitive the sequence is to diffusion effects. Higher b-values (e.g., b=1000) are also optimum for background signal suppression[12,14,15] .

       However, one of the disadvantages of qualitative assessment at index DWI is that the signal intensity depends on both water mobility and T2 relaxation time (also known as "T2 shine-through" effect). "T2 shine-through" effect can result in high signal intensity on high b-value DWI images without restricted diffusion. This may result in image interpretation errors, particularly if the ADC maps are not examined. ADC maps, which are actually a quantitative measure of tissue diffusivity, can also be visually inspected. Tissues with restricted diffusion appear hypointense on ADC maps/images, while they remain hyperintense on DWI. However, "T2 shine through" effect will result in a hyperintense signal in a tissue on both DWI as well as ADC maps[3,12] . This effect can be sometimes reduced by the choice of an appropriate TE (a short one) and b-value (a large one), but it cannot be easily avoided. For prostate tissues, b-values >1000 s/mm2 are occasionally needed to decrease the effects of "T2-shine through" [16].

       In clinical practice, however, qualitative assessment of DWI during imaging interpretation by radiologists is of critical importance because quantitative analysis of DWI requires additional time. A few published articles on DWI at 3 T or 1.5 T showed that for qualitative assessment of PCa, the peripheral zone (PZ) and transition zone (TZ) showed low signal intensity relative to benign prostate tissues on ADC maps, which indicates that DWI could have incremental value relative to conventional T2-weighted imaging[17]. Moreover, these authors used ADC maps to predict localized PCa instead of index DWI to avoid the "T2-shine through" effect. A recent study reported the additional utility of DWI when used together with T2-weighted imaging at 3 T for predicting PCa localization in 68 tumors[17]. In this study, the overall sensitivity and positive predictive value of T2-weighted imaging plus DWI were 84% and 86%, respectively, whereas those of T2-weighted imaging alone were 66% and 63%, respectively (P<0.05).

3.2 Quantitative analysis of DWI

       Quantitative analysis of DWI can be performed by calculating the ADC. The logarithm of tissue relative signal intensity (signal decay) on the y-axis against the b-values on the x-axis results in a line (exponential function). The slope of this line represents the ADC. ADC is a quantitative measure of tissue diffusivity and is expressed in (×10-3) as mm2/s. This graphical fit can be improved by using multiple b-values to reduce error involved in the calculation and monoexponential and multiexponential modeling of signal decay[9]. Quantitative analysis has advantages over visual qualitative analysis in that it is independent of magnetic field strength and can overcome the effects of "T2 shine-through" [12]. A simple method to detect T2 shine-through is to use the "exponential image" formula, where an increased signal ratio [DWI signal intensity (at b=X)/unweighted signal intensity (at b=0)] suggests true restricted diffusion[12]. The ADC is calculated for each pixel and displayed as a parametric map. An average ADC value can be obtained by drawing an electronic ROI, as mentioned above. Certain tissue characteristics, such as increased cellularity and ischemia, are known to be associated with low ADC values due to restricted diffusion of water[12] .

       PCa is histologically characterized by a higher cellular density than the normal prostate tissue, with replacement of the normal glandular tissue; thus, it is expected to show a more restricted diffusion of water molecules, compared with normal prostatic gland[18]. Which will cause the PCa lesion displayed as a lower intensity area in the ADC maps, compared to the normal prostate gland areas[19]. The ADC value of BPH is significantly lower than that of normal central gland (CG) of the prostate[20]. This can be cause by CG tissue in patients with BPH may contain more stroma tissue and accordingly less glandular components than healthy CG tissue.

       Some studies using ADC value to differentiate the PCa in different region of the prostate. For example, Kim et al[21], reported that according to receiver operating characteristic analysis for the prediction of PCa, an ADC cutoff value of 1.67 × 10-3 mm2/s had 0.97 area under the curve (AUC) in PZ cancer. For the prediction of TZ cancer, an ADC cutoff value of 1.61 × 10-3 mm2/s showed 0.92 AUC. Some other studies using ADC value to differentiate the PCa lesion with other prostate abnormalities like BPH and prostatitis. For example, Liu et al[20], reported that according to receiver operating characteristic analysis for discriminating PCa from BPH, the AUC of ADC was 0.92 at a cutoff of 0.91 × 10-3 mm2/s. When making a distinction between PCa and prostatitis, the AUC of ADC was 0.99 at a cutoff of 1.13 × 10-3 mm2/s.

       Several authors have demonstrated that malignant lesions (range, 0.49±0.13-1.66±0.32 × 10-3 mm2/s) have approximately 20 to 60% lower ADC values than noncancerous tissue (range, 1.26±0.27—2.19±0.24 × 10-3 mm2/s) in the PZ of the prostate, depending on patient population characteristics and technical issues[4,5,21,22,23,24,25,26,27,28,29,30,31,32,33,34]. Based on the literature, DWI alone has a respectively sensitivity and specificity of 81.0%—94.0% and 72.2%—91.0% with a cut-off ADC value of 1.45—1.67 × 10-3 mm2/s for tumor detection, at 1.5 or 3 T [21, 26, 32]. The variation of ADC value that shown above may be related to the strength of the diffusion gradient (300—1000 s/mm2), technical parameters utilized, and the magnetic field (1.5 or 3 T) used[35]. Although the mean ADC values of PCa DWI were significantly lower than the benign prostatic tissues, there are some overlaps found between the PCa and benign prostatic tissues. Thus, the use of ADC values alone could result in the misdiagnosis of PCa.

3.3 Choices of b-value in monoexponential model

       The b-value is one of the most important parameters that can affect PCa detection capability[36]. To obtain more accurate information about prostate tumors, an appropriate b-value is essential for producing high-quality ADC maps that affect the accuracy of ADC measurements and visual imaging interpretations. However, there are conflicting opinions as to the optimal b-value for tumor detection[37,38]. Beside choosing a b-value of 0 and a second one in the 600-1000 s/mm2 range, some study have been used more than two b-values[39,40] and upper values greater than 1000 s/mm2 for analysis as well[40]. Different choices of b-values as well as different underlying diffusion models[39] will generally followed by variations in the resulting absolute ADC values. In addition, there is also evidence that the choice of b-values has a significant influence on visual analysis, in particular on the lesion delineation and visual ADC contrast. Katahira et al[41] and Metens et al[37], reported improved utility of acquired DWI images using an ultra-high b-value of 2000 s/mm2 compared those with using a standard b-value of 1000 s/mm2, whereas Kitajima et al[38], observed no benefit of ADC maps obtained with the higher b-value. Rosenkrantz et al[42], showed that using a b-value of 2000 s/mm2 compared with a b-value of 1000 s/mm2 resulted in improved tumor sensitivity and higher tumor-to-peripheral zone contrast on the DWI images, whereas performance of the ADC maps corresponding to the two b-values was similar. For standardization, it is crucially important to identify an optimal b-value of prostate DWI for detection of PCa[41]. A b-value of 1500 s/mm2 has not been reported as frequently as those of 1000 or 2000 s/mm2. Metens et al[37], reported that the contrast and image quality were improved in b=1500 s/mm2 images compared to b=1000 or 2000 s/mm2, and Wang et al[11], concluded DWI images and ADC map using b=1500 s/mm2 should be considered more effective than those with b=2000 or b=1000 s/mm2 for detecting PCa.

3.4 Intravoxel incoherent motion (IVIM) model

       The IVIM model, introduced by Le Bihan et al[43] in 1988, the water molecules motion due to blood microcirculation in the capillary network (perfusion) has a similar impact on the MRI signal intensity as their motion caused by the molecular diffusion, that utilized by low b values. IVIM DWI obtained by using biexponential decay function[44,45]. The study of Shinmoto et al[44], showed that IVIM DWI parameters are significantly different between PCa and PZ. IVIM DWI may offer additional information for tissue characterization in the prostate gland. Thus, in the study performed by Dopfert et al[45], shown that compared to ADC, IVIM method still has lower diagnostic performance for PCa detection.

4 Limitations of prostate DWI

       Although prostate DWI can be useful in evaluating patients with PCa, current prostate DWI at both 1.5 and 3 T still has several limitations to overcome[9]. First, the lack of standardization with respect to technical parameters utilized, such as pulse sequence type, TR, TE, b-values utilized, gradient direction and modeling method of signal decay, are major challenges to the reproducibility and reliability of DWI and measured ADC values. In many institutions, various methods are applied for prostate DWI using various b factors, which result in various ADC values being reported for PCa. Second, even though prostate DWI has been used in a clinical setting to assess PCa, only a few studies investigating its reproducibility have been published. Third, DWI has inherent flaws, such as imaging distortions and susceptibility artifacts. These flaws make assessing the therapeutic responses after hormonal or radiation therapy in PCa challenging. To overcome or decrease the impact of these problems, more advanced software and hardware need to be developed. Fourth, DWI plays limited role in the local staging of disease, primarily due to its low spatial resolution compared to conventional spin-echo techniques. Fifth, more in vivo studies are required to determine and clarify the pathologic changes related to the features observed at DWI.

5 Future directions of prostate DWI

       In terms of future research directions, 3 T DWI should be used to evaluate PCa using biexponential analysis that use b-values higher than 1000 s/mm2, diffusion tensor imaging (DTI), and diffusion-weighted whole-body imaging with background body signal suppression (DWIBS). Theoretically, monoexponential analysis, which assumes an inverse linear logarithmic relationship between signal intensity and b-values, could fail to differentiate between the fast and slow components of diffusion. The fast diffusion component is studied at lower b-values. The slow diffusion component is studied at relatively higher b-values (b> 1000 s/mm2)[39]. The biexponential method of diffusion analysis theoretically eliminates the effects of perfusion, reflecting tissue diffusion characteristics to a closer degree[39]. Further studies are required to show biexponential analysis has significant benefit over monoexponential analysis in clinical practice. DWIBS is a recently introduced application of DWI that is performed using a STIR EPI diffusion-weighted technique with background suppression[46,47]. At 3 T, DWIBS potentially offers higher SNR because SNR increases linearly with increasing field strength[48]. However, larger susceptibility-induced image distortion and signal intensity losses, stronger blurring artifacts, and more pronounced motion artifacts degraded the imaging quality at 3 T. More studies are needed to determine the potential role of DWIBS in PCa. In vivo diffusion tensor imaging (DTI) of the prostate gland is feasible, including that at 3 T, based on the fact that the motion of water molecules is not truly random, but follows the orientation of the tissue structure (anisotropy)[49,50]. PCa theoretically disrupts this normal anisotropy. Limitations of DTI include variation of noise, long imaging times and specific absorption rate limits[49]. More studies are required to evaluate the role of 3 T DTI in the clinical evaluation of PCa.

6 Conclusion

       DWI is a promising and useful noninvasive imaging method that provides qualitative and quantitative information related to tumor cellularity, tissue structure and the integrity of the cellular membrane in PCa. It could help us to improve the PCa detection and localization which also could decrease the excessive biopsy rate. It also may be helpful in differentiating PCa from other benign prostate abnormalities like BPH and prostatitis. But there are still some limitations of this method that needed to overcome, especially the standardization and optimization of the various technical parameters to have a better accuracy and universal standard value which needed to be further researched to establish it. In the clinical settings, DTI, and DWIBS at 3 T have a valuable potential to better evaluate the PCa; however, further studies are still required.

[1]
Stewart BW, Wild CP. World cancer report 2014. France: International Agency for Research on Cancer, 2014: 453-454.
[2]
Aydin H, Kizilgoz V, Tatar IG, et al. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr, 2012, 36(1): 30-45.
[3]
Lim KS, Tan CH. Diffusion-weighted MRI of adult male pelvic cancers. Clin Radiol, 2012, 67(9): 899-908.
[4]
Yagci AB, Ozari N, Aybek Z, et al. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol, 2011, 17(2): 130-134.
[5]
AbdelMaboud NM, Elsaid HH, Aboubeih EA. The role of diffusion: weighted MRI in evaluation of prostate cancer. Egyp J Radiol Nucl Med, 2014, 45(1): 231-236.
[6]
Hekimoğlu B, Aydin H, Kızılgöz V, et al. Identification and localization of prostate cancer with combined use of T2-weighted, diffusion weighted MRI and proton MR spectroscopy, correlation with histopathology. Adv J Mol Imaging, 2013, 3(3): 23-36.
[7]
Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology, 2011, 261(1): 46-66.
[8]
Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol, 2007, 189(2): 323-328.
[9]
Morani AC, Elsayes KM, Liu PS, et al. Abdominal applications of diffusion-weighted magnetic resonance imaging: where do we stand. World J Radiol, 2013, 5(3): 68-80.
[10]
Kim CK, Park BK, Kim B. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol, 2010, 194(6): 1461-1469.
[11]
Wang X, Qian Y, Liu B, et al. High-b-value diffusion-weighted MRI for the detection of prostate cancer at 3 T. Clin Radiol, 2014, 69(11): 1165-1170.
[12]
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol, 2007, 188(6): 1622-1635.
[13]
Thormer G, Otto J, Reiss-Zimmermann M, et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol, 2012, 22(8): 1820-1828.
[14]
Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 2008, 18(9): 1937-1952.
[15]
Kele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol, 2010, 16(13): 1567-1576.
[16]
Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia, 2009, 11(2): 102-125.
[17]
Kim CK, Park BK, Lee HM, et al. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol, 2007, 42(12): 842-847.
[18]
Petralia G, Thoeny HC. DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging, 2010, 10(1A): S112-S123.
[19]
Yamamura J, Salomon G, Buchert R, et al. MR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (H) MR spectroscopy in comparison with histology. Radiol Res Pract, 2011, 2011: 616852.
[20]
Liu X, Peng W, Zhou L, et al. Biexponential apparent diffusion coefficients values in the prostate: comparison among normal tissue, prostate cancer, benign prostatic hyperplasia and prostatitis. Korean J Radiol, 2013, 14(2): 222-232.
[21]
Kim CK, Park BK, Han JJ, et al. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr, 2007, 31(3): 449-454.
[22]
Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol, 2007, 188(1): 91-98.
[23]
Kitajima K, Kaji Y, Kuroda K, et al. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci, 2008, 7(2): 93-99.
[24]
Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging, 2009, 29(6): 1360-1366.
[25]
Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology, 2008, 246(2): 480-488.
[26]
Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol, 2006, 41(2): 185-188.
[27]
Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging, 2002, 16(2): 196-200.
[28]
Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging, 2005, 21(3): 258-262.
[29]
Kim JH, Kim JK, Park BW, et al. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging, 2008, 28(5): 1173-1179.
[30]
Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol, 2009, 44(9): 572-576.
[31]
Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU international, 2009, 103(7): 883-888.
[32]
desouza NM, Reinsberg SA, Scurr ED, et al. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol, 2007, 80(950): 90-95.
[33]
Tanimoto A, Nakashima J, Kohno H, et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging, 2007, 25(1): 146-152.
[34]
Wang LW, Wang M, Wang SJ, et al. The value of magnetic resonance diffusion weighted imaging in the diagnosis of prostate cancer. Chin J Magn Reson Imaging, 2014, 5(3): 198-201.
王利伟,王牧,王绍娟,等. MR扩散加权成像诊断前列腺癌的价值分析.磁共振成像, 2014, 5(3): 198-201.
[35]
Kilickesmez O, Cimilli T, Inci E, et al. Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn Interv Radiol, 2009, 15(2): 104-110.
[36]
Simpkin CJ, Morgan VA, Giles SL, et al. Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume. Br J Radiol, 2013, 86(1024): 20120469.
[37]
Metens T, Miranda D, Absil J, et al. What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3 T?Eur Radiol, 2012, 22(3): 703-709.
[38]
Kitajima K, Takahashi S, Ueno Y, et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm) and standard high b-value (1000 s/mm). J Magn Reson Imaging, 2012, 36(1): 198-205.
[39]
Riches SF, Hawtin K, Charles-Edwards EM, et al. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed, 2009, 22(3): 318-325.
[40]
Shinmoto H, Oshio K, Tanimoto A, et al. Biexponential apparent diffusion coefficients in prostate cancer. Magn Reson Imaging, 2009, 27(3): 355-359.
[41]
Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol, 2011, 21(1): 188-196.
[42]
Rosenkrantz AB, Hindman N, Lim RP, et al. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging, 2013, 38(3): 694-700.
[43]
Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology, 1988, 168(2): 497-505.
[44]
Shinmoto H, Tamura C, Soga S, et al. An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer. AJR Am J Roentgenol, 2012, 199(4): W496-W500.
[45]
Dopfert J, Lemke A, Weidner A, et al. Investigation of prostate cancer using diffusion-weighted intravoxel incoherent motion imaging. Magn Reson Imaging, 2011, 29(8): 1053-1058.
[46]
Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med, 2004, 22(4): 275-282.
[47]
Gong JY, Zhou ZY, Deng YH, et al. The application value of whole body diffusion-weighted imaging in tumor lesions. Chin J Magn Reson Imaging, 2013, 4(6):420-425.
龚佳英,周智洋,邓艳红,等. MR全身扩散加权成像技术在肿瘤病变中的应用价值.磁共振成像, 2013, 4(6): 420-425.
[48]
Murtz P, Krautmacher C, Traber F, et al. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol, 2007, 17(12): 3031-3037.
[49]
Gurses B, Kabakci N, Kovanlikaya A, et al. Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol, 2008, 18(4): 716-721.
[50]
Wang Q, Fang JF, Wang B. Prostate cancer: theoretical base of MR diffusion tensor imaging study. Chin J Magn Reson Imaging, 2015, 6(1): 76-80.
王倩,房俊芳,王滨.磁共振扩散张量成像诊断前列腺癌的理论基础.磁共振成像, 2015, 6(1): 76-80.

上一篇 MRI在直肠癌诊疗中的发展过程与应用
下一篇 积极开展定量动态增强磁共振成像研究
  
诚聘英才 | 广告合作 | 免责声明 | 版权声明
联系电话:010-67113815
京ICP备19028836号-2